| [1］ Yokota S，Imagawa T，Murata T，et al. Guidance on the use of adalimumab for juvenile idiopathic arthritis in Japan［J］. Mod Rheumatol，2012，22（4）：491-497. [2］ Trachana M，Pratsidou-Gertsi P，Pardalos G，et al. Safety and efficacy of adalimumab treatment in Greek children with juvenile idiopathic arthritis［J］. Scand J Rheumatol， 2011，40（2）：101-107. [3］ Lovell DJ，Ruperto N，Goodman S，et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis［J］. N Engl J Med，2008，359（8）：810-820. [4］ Beukelman T， Patkar NM， Saag KG， et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis： initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features［J］. Arthritis Care Res（Hoboken），2011，63（4）：465-482. [5］ Giannini EH，Ruperto N，Martini A，et al. Preliminary definition of improvement in juvenile arthritis［J］. Arthritis Rheum，1997，40：1202-1209. [6］ Ungar WJ，Costa V，Burnett HF，et al. The use of biologic response modifiers in polyarticular-course juvenile idiopathic arthritis：a systematic review［J］. Semin Arthritis Rheum，2013，42（6）：597-618. [7］ Kemper AR，Van Mater HA，Coeytaux RR，et al. Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis［J］. BMC Pediatr，2012，12：29. [8］ Trachana M，Pratsidou-Gertsi P，Pardalos G，et al. Safety and efficacy of adalimumab treatment in Greek children with juvenile idiopathic arthritis［J］. Scand J Rheumatol，2011，40（2）：101-107. [9］ Sevcic K，Orban I，Brodszky V，et al. Experiences with tumour necrosis factor-{alpha} inhibitors in patients with juvenile idiopathic arthritis：Hungarian data from the National Institute of Rheumatology and Physiotherapy Registry［J］. Rheumatology（Oxford），2011，50（7）：1337-1340. [10］ Imagawa T，Takei S，Umebayashi H，et al. Efficacy， pharmacokinetics， and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan［J］. Clin Rheumatol，2012，31（12）：1713-1721. [11］ Anink J，Otten MH，Gorter SL，et al. Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis：etanercept or adalimumab?［J］. Rheumatology （Oxford），2013，52（9）：1674-1679. [12］ Simonini G，Taddio A，Cattalini M，et al. Superior efficacy of adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug： adalimumab as starting anti-TNF-alpha therapy in childhood chronic uveitis［J］. Pediatr Rheumatol Online J，2013，11（1）：16. [13］ Magli A，Forte R，Navarro P，et al. Adalimumab for juvenile idiopathic arthritis-associated uveitis［J］. Graefes Arch Clin Exp Ophthalmol，2013，251（6）：1601-1606. [14］ Burmester GR， Remo P， Gordon KB， et al. Adalimumab：long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis，juvenile idiopathic arthritis，ankylosing spondylitis，psoriatic arthritis，psoriasis and Crohn’s disease［J］. Ann Rheum Dis，2013，72：517-524. [15］ de Moraes JC，Aikawa NE，Ribeiro AC，et al. Immediate complications of 3，555 injections of anti-TNFα［J］. Rev Bras Reumatol，2010，50（2）：165-175. [16］ Perman MJ，Lovell DJ，Denson LA，et al. Five cases of anti-tumor necrosis factor alpha-induced psoriasis presenting with severe scalp involvement in children［J］. Pediatr Dermatol，2012，29（4）：454-459. [17］ Park JH，Lee J，Lee JH，et al. Lymphomatoid papulosis in a patient treated with adalimumab for juvenile rheumatoid arthritis［J］. Dermatology，2012，225（3）：259-263. |
